VAL.L Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 liep. 2024 @ 11:12):
Our systems believe the stock currently is overvalued by -0.15% compare to its pairs and should correct downwards.

Stats
Dzisiejszy wolumen	154 542
Średni wolumen	1.86M
Kapitalizacja rynkowa	4.17M
EPS	£-0.00980 ( Q4 \| 2023-12-31 )
Następna data zysków	( £0 ) 2024-08-21
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.570 (Sector) 0 (Industry) 0
ATR14	£0.0990 (3.14%)

AMYT.L -11.73%

APH.L 0.39%

AVCT.L -0.27%

AZN.L -0.36%

BMK.L 7.59%

BVXP.L -2.16%

C4XD.L 27.32%

CIR.L 0.00%

CLIN.L 0.11%

DEST.L -2.51%

DPH.L 0.05%

EAH.L 3.49%

ERGO.L 0.15%

ETX.L -6.74%

EVG.L 2.25%

FAB.L -1.59%

FARN.L -5.08%

FUM.L 0.27%

GDR.L 3.03%

GNS.L 1.45%

GSK.L -0.51%

HCM.L -0.36%

HEMO.L 0.23%

HIK.L -0.58%

IMM.L -1.15%

INDV.L 0.32%

IXI.L -5.25%

MTPH.L 1 794.74%

MXCT.L -2.17%

N4P.L -4.71%

NCYT.L -2.42%

NFX.L -4.71%

OBD.L 0.92%

OKYO.L -24.32%

ONC.L 0.45%

OPTI.L -3.75%

OVB.L -2.22%

OXB.L 2.58%

PRM.L -4.82%

PRTC.L 0.22%

PYC.L -6.25%

REDX.L 31.58%

RENE.L -2.17%

SAR.L 7.00%

SCLP.L -1.86%

SLN.L -0.93%

SNG.L 3.48%

STX.L 2.70%

TILS.L 8.33%

TRX.L -1.15%

VAL.L 0.00%

VEC.L 0.00%

Korelacja (AI algo v.1.1b): Overvalued: -0.15% £3.15 paired level. (Algorytm śledzi zmiany najbardziej skorelowanych akcji w czasie rzeczywistym i natychmiast aktualizuje)

ValiRx PLC Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ValiRx PLC Finanse

Annual	2023
Przychody:	£9 600.00
Zysk brutto:	£-246 043 (-2 562.95 %)
EPS:	£-0.0201

FY	2023
Przychody:	£9 600.00
Zysk brutto:	£-246 043 (-2 562.95 %)
EPS:	£-0.0201

FY	2022
Przychody:	£0
Zysk brutto:	£-224 268 (0.00 %)
EPS:	£-0.0311

FY	2021
Przychody:	£0.00
Zysk brutto:	£0.00 (0.00 %)
EPS:	£-0.0401

Financial Reports:

No articles found.

ValiRx PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

ValiRx PLC

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.